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ABSTRACT
Background: Interleukin 33 (IL-33) works as a functional mediator in allergic disease by enhancing the activ-
ity of eosinophils and inducing expression of T helper 2 (Th2)-associated cytokines. However, the role of IL-33
in pulmonary eosinophilia has not been elucidated. We investigated the levels of IL-33 in eosinophilic pneumo-
nia (EP) together with associated cytokines, and discussed the clinical significance of IL-33 in EP.
Methods: Sera and bronchoalveolar lavage fluid (BALF) were obtained from 16 patients with EP, including
acute eosinophilic pneumonia (AEP) and chronic eosinophilic pneumonia (CEP). Twelve patients with acute
respiratory distress syndrome (ARDS) were also included for comparison. The concentration of IL-33 and Th2
cytokines (IL-4, IL-5, IL-13) were measured by enzyme-linked immunosorbent assay (ELISA).
Results: The concentration of serum IL-33 was significantly higher in patients with AEP than in CEP. In CEP,
only patients with atopic factors showed mild increase of serum IL-33. The concentration of BALF IL-33 was
also significantly elevated in AEP, however, it remained quite low in CEP. Among Th2 cytokines, IL-5 was sig-
nificantly increased in both serum and BALF in AEP, and the level of IL-5 was positively correlated with that of
IL-33. ARDS showed no increase of serum and BALF IL-33.
Conclusions: The remarkable increase of BALF IL-33 in AEP indicated the local production of IL-33 in lungs.
IL-33 is considered to be a local key molecule for triggering pulmonary eosinophilia, together with IL-5. BALF
IL-33 appears to be a useful marker for discriminating AEP from CEP and ARDS.
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INTRODUCTION
IL-33 is a new functional cytokine belonging to the IL-
1 cytokine family,1 and was first identified as a ligand
of ST2L, which is the molecule related to various al-
lergic and inflammatory reactions.2-4 The main func-
tions of IL-33 identified so far by in vitro studies are
the induction of Th2-associated cytokine expression
in Th2-polarized naïve T cells1 and the activation of
eosinophils as well as IL-5.5,6 In animal models,
Schmitz et al. first demonstrated that the administra-
tion of IL-33 induced an increase of eosinophils and
mononuclear cells in blood, and infiltration of eosino-
phils around pulmonary vessels.1 Kondo et al. and
Oboki et al. also showed that administration of IL-33
directly induced airway eosinophilia and hyper-
responsiveness like bronchial asthma, even in RAG
2 -- mice lacking T cells and B cells.7,8 In humans,
there are several clinical studies focusing on IL-33;
Sakashita et al. reported an increase of serum IL-33
level and polymorphism of IL-33 gene were found in
patients with Japanese cedar pollinosis,9 Prefontaine
et al. showed that the expression of IL-33 in airway
smooth muscle cells was increased in association
with the severity of bronchial asthma,10 and the pre-
sent authors previously published data describing an
increase of serum IL-33 levels in severe atopic
asthma.11 From these evidences, it has been estab-
lished that IL-33 works as an important mediator in al-
lergic airway disease. On the other hand, thus far, the
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clinical behavior and implications of IL-33 in pulmo-
nary eosinophilia have not been elucidated. There-
fore, we focused our attention on eosinophilic pneu-
monia (EP) and investigated the level of IL-33.
EP is clinically subdivided into acute eosinophilic
pneumonia (AEP) and chronic eosinophilic pneumo-
nia (CEP).12-14 Although both EPs show remarkable
eosinophilia in the lung tissue, they are quite differ-
ent in their clinical course and pathological find-
ings.15,16 There have been several basic studies to
compare AEP with CEP; the numbers of lymphocytes
and IL-5 and eotaxin levels in BALF were significantly
increased in AEP.15,17-19 However, at present, their
etiologies are still unknown and the biological mark-
ers to distinguish them have not been established.
Therefore, in this study, we compared the levels of
IL-33 and related cytokines in AEP and CEP, and dis-
cussed the difference between them.
Pathological findings of AEP have traditionally
been characterized as diffuse alveolar damage, simi-
lar to those of acute lung injuryacute respiratory dis-
tress syndrome (ALIARDS).12 In addition, because
the radiological findings of AEP also resemble the in-
itial phase of ARDS by reflecting pulmonary intersti-
tial edema, and peripheral eosinophila is generally
lacking in the initial phase of AEP, distinguishing
AEP from ARDS is sometimes clinically difficult.
Therefore, we also had an interest in the IL-33 levels
in patients with ARDS and investigated as well as EP.
METHODS
SUBJECTS
Sixteen patients with EP who had been admitted and
treated at Jichi Medical University Hospital between
2000 and 2011 were selected. These 16 patients in-
cluded 4 patients with AEP and 12 patients with CEP.
Twelve healthy non-atopic adult volunteers were in-
volved as controls. Twelve patients with ARDS were
also analyzed. Each patient was treated at Jichi Medi-
cal University Hospital between 2000 and 2009. AEP
patients were selected according to the criteria pro-
posed by Allen et al.13 and Philit et al..20 CEP was di-
agnosed according to Carrington’s original criteria14
and the recent criteria by Jederlinic et al. and Mochi-
maru et al..16,21 ARDS was diagnosed according to the
North American-European Consensus Conference
definition for ARDS22: namely, acute onset of illness,
bilateral opacities on chest radiograph, a PaO2FIO2
ratio (PF ratio) of less than 200, and no clinical evi-
dence of left heart failure. ARDS was caused by multi-
ple etiologies; the underlying disease was severe
pneumonia in 6 patients, sepsis in 5, and rickettsia in-
fection in 1. All patients were examined by chest X-
ray and high-resolution CT scan at admission. The ra-
diological findings in this study were reviewed by 2
pulmonologists and 1 radiologist in order to confirm
diagnoses. This study was conducted according to
the principles expressed in the Declaration of Hel-
sinki, and the protocol of study was approved by the
Ethical Committee of Jichi Medical University. In-
formed consent for participation was obtained from
each patient.
COLLECTION OF BLOOD SAMPLE
Blood samples were obtained at admission, and the
numbers of leukocytes and eosinophils were counted
by a COULTER LH750 analyzer (Beckman Coulter,
USA). Then, the sera of the patients were separated
after centrifugation at 1500 × g at 4℃ for 10 min and
stored at -80℃ until use.
BRONCHOALVEOLAR LAVAGE AND PREPARA-
TION OF BALF
Bronchoalveolar lavage (BAL) was collected in the in-
volved lung segment of patients with EP. Fifty-ml ali-
quots of saline solution were instilled three times and
recovered. The total number of cells was immediately
counted, and for the determination of cell types, cell
components obtained after centrifugation in a cyto-
spin at 120 × g for 10 min were stained with Diff-
Quick (Sysmax, Kobe, Japan). The remaining BALF
was centrifuged at 400 × g for 10 min at 4℃ and the
supernatant was collected and frozen at -80℃ until
the analysis.
MEASUREMENT OF CYTOKINES AND IgE
Cytokines (IL-4, IL-5, IL-13, IL-33) were measured us-
ing enzyme-linked immunosorbent assay (ELISA)
kits (IL-33; R&D Systems, MN, USA, IL-4 and IL-5;
Biosource, CA, USA, IL-13; Invitrogen, CA, USA).
The minimum detectable level of each ELISA was as
follows: IL-4 < 2 pgml, IL-5 < 4 pgml, IL-13 < 4 pg
ml, and IL-33 < 3.9 pgml. IgE was analyzed by fluo-
rescence enzyme immunoassay.
STATISTICAL ANALYSIS
Data are presented as means ± standard deviations.
Statistical analysis was performed using Mann-
Whitney’s U test for comparing two groups or by
ANOVA followed by Turkey’s test for comparing mul-
tiple groups. The r correlation coefficient test was de-
termined by Pearson’s correlation test. SPSS 11.0J
(SPSS Inc., Chicago, IL, USA) was used for statistical
analysis. All statistical tests were 2-sided and p values
< 0.05 were considered statistically significant.
RESULTS
CLINICAL FEATURES OF EP PATIENTS
The sex and the mean ages, duration of symptoms
(duration from first symptom to diagnosis), titers of
PaO2 and serum IgE, numbers of leukocytes and
eosinophils in the peripheral blood and total cell
counts and numbers of eosinophils in BALF are listed
in Table 1. As described in the Table 1, the duration
from the first symptom to diagnosis was significantly
longer in CEP than in AEP. In AEP, the numbers of
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Table　1　Clinical features of subjects
healthy (n = 12) AEP (n = 4) CEP (n = 12)
Age (years old) 47.5 ± 23.3  22.0 ± 1.7  51.8 ± 22.8
M/F 9/3 4/0 6/6
Duration of symptoms (days) N.A.   2.7 ± 0.5  27.8 ± 13.0*
PaO2 (Torr) N.A.  45.3 ± 8.4*  74.5 ± 14.0
WBC (×103/μl) 5.1 ± 1.0  18.8 ± 6.8†  11.7 ± 3.7
Eosinophil (×103/μl) 0.7 ± 0.6   0.3 ± 0.1   3.7 ± 2.3†*
IgE (IU/ml) 22.2 ± 22.3 799.8 ± 874.1 987.8 ± 1164.1
CRP (mg/dl) 0.03 ± 0.03  16.2 ± 7.2†*   6.1 ± 6.8
BALF Total Cell (×105/ml) N.A.  10.2 ± 4.2  29.3 ± 27.3
BALF Eosinophil (×105/ml) N.A.   4.2 ± 1.0  18.1 ± 26.2
N.A., not assessment. †p < 0.05, compared with healthy, *p < 0.05, compared with CEP.
leukocytes and CRP were markedly elevated and res-
piratory failure was more severe. On the other hand,
CEP showed eosinophilia in both peripheral blood
and BALF, whereas in AEP eosinophilia was shown
in BALF only. There were no significant differences
in IgE levels between AEP and CEP.
CONCENTRATION OF IL-33 IN THE PATIENTS
WITH EP
We first compared the concentrations of serum IL-33
in healthy controls and all EP patients. The serum IL-
33 levels in EP patients were 447.7 ± 745.6 pgml,
much higher than those in controls (27.1 ± 39.9 pg
ml) (Fig. 1a). However, the values of IL-33 in EP were
widely distributed, so that the difference in IL-33 lev-
els between EP and controls was not statistically sig-
nificant.
Then, EP patients were divided into AEP and CEP,
and separately reanalyzed. The AEP group showed a
significant elevation of serum IL-33 (1344.0 ± 1095.0
pgml) compared with controls and CEP (148.9 ±
203.9 pgml in CEP) (Fig. 1b). In addition, AEP also
showed significant elevation of BALF IL-33 (394.7 ±
318.8 pgml). By contrast, the levels of BALF IL-33 in
CEP were very low and almost undetectable (0.09 ±
0.24 pgml) (Fig. 1c).
In the present study, each one case of AEP and
CEP was accompanied with pleuritis. We obtained
pleural effusion by thoracocentesis and measured the
level of IL-33; it was 681.7 pgml in the AEP patient
but undetectable in the CEP patient.
CONCENTRATION OF Th2 CYTOKINES IN EP
IL-4, IL-5 and IL-13 are known as representative Th2
cytokines induced by IL-33.1 Here, we examined the
levels of these cytokines in both serum and BALF.
In all healthy controls and CEP patients, each se-
rum IL-4 level was under the detectable level in the
present assay system; in contrast, only serum IL-4 in
AEP was detectable (3.68 ± 3.78 pgml) (Fig. 2a). On
the other hand, BALF IL-4 was detected in both
groups, but there were no significant differences be-
tween these levels in AEP and CEP (AEP; 3.73 ± 3.24
pgml, CEP; 1.67 ± 0.64 pgml) (Fig. 2b).
In contrast, serum IL-5 was significantly higher in
AEP (AEP, 1000.6 ± 356.8 pgml) than in other sub-
jects (healthy, 6.39 ± 8.92 pgml; CEP, 19.7 ± 25.7 pg
ml) (Fig. 3a). In BALF analysis, AEP also showed a
significant increase of IL-5 (AEP, 717.0 ± 698.9 pgml;
CEP, 38.4 ± 38.8 pgml) (Fig. 3b).
Serum and BALF IL-13 were detectable in both
AEP and CEP; however, only serum IL-13 in AEP
showed a statistically significant increase compared
with other groups (Fig. 4a, b). Titers of serum IL-13
were 3.7 ± 5.5 pgml in healthy controls; 34.2 ± 55.9
pgml in AEP, and 3.9 ± 6.9 pgml in CEP; BALF IL-
13 values were 24.0 ± 34.2 in AEP and 4.2 ± 4.0 pgml
in CEP.
In correlation analyses between Th2 cytokines and
IL-33 in patients with EP, only the concentration of IL-
5 was significantly correlated with that of IL-33 in
both serum (r = 0.673, p = 0.003) and BALF (r = 0.729,
p = 0.032) (Fig. 3c, d).
CONCENTRATION OF IL-33 IN PATIENTS WITH
ARDS
We also examined the levels of IL-33 in patients with
ARDS in this study. The clinical features and the level
of IL-33 in ARDS are listed and compared with that of
AEP in Table 2. Every patient with ARDS showed an
increase of of the number of leukocytes and CRP as
well as AEP. Their respiratory failure was more se-
vere and PF ratios were consistent with the interna-
tional criteria of ARDS (91.4 ± 23.8). However, their
serum IL-33 levels were not elevated (1.0 ± 2.9 pg
ml), a value equivalent to those of healthy controls.
BALF IL-33 was also difficult to detect (2.4 ± 6.2 pg
ml).
UNDERLYING ATOPIC DISEASE AND SERUM IL-
33 LEVEL IN CEP
In CEP, the high standard deviation of serum IL-33
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Fig.　1　(a) Concentration of IL-33 in serum. Samples were obtained from healthy volunteers (healthy), pa-
tients with eosinophilic pneumonia (EP). Data are presented as the mean ± SD. healthy: n = 12, EP: n = 16. 
(b) Concentration of IL-33 in serum. Samples were obtained from healthy volunteers (healthy), patients with 
acute eosinophilic pneumonia (AEP) and chronic eosinophillic pneumonia (CEP). Data are presented as 
mean ± SD. healthy: n = 12, AEP: n = 4, CEP: n = 12. **p < 0.01, compared with healthy. *p < 0.05, com-
pared with CEP. (c) Concentration of IL-33 in BALF. Samples were obtained from patients with AEP and 
CEP. Data are presented as the mean ± SD. AEP: n = 4, CEP: n = 12. **p < 0.01, compared with CEP.
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Fig.　2　(a) Concentration of IL-4 in serum. Samples were obtained from healthy volunteers 
(healthy), AEP and CEP. Data are presented as the mean ± SD. healthy: n = 12, AEP: n = 4, 
CEP: n = 12. *p < 0.05, compared with healthy and CEP. (b) Concentration of IL-4 in BALF. 
Samples were obtained from patients with AEP and CEP. Data are presented as the mean ± 
SD. AEP: n = 4, CEP: n = 12.
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Fig.　3　(a) Concentration of IL-5 in serum. Samples were obtained from healthy volunteers (healthy), AEP 
and CEP. Data are presented as the mean ± SD. healthy: n = 12, AEP: n = 4, CEP: n = 12. *p < 0.05, com-
pared with CEP. (b) Concentration of IL-5 in BALF. Samples were obtained from patients with AEP and CEP. 
Data are presented as the mean ± SD. AEP: n = 4, CEP: n = 12. *p < 0.05, compared with CEP. (c) Correla-
tion analysis was determined by Pearson’s correlation test. The correlations between serum IL-33 and IL-5 
levels in EP were analyzed (n = 16). (d) Correlation analysis was determined by Pearson’s correlation test. 
The correlations between BALF IL-33 and IL-5 levels in EP were analyzed (n = 16).
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Fig.　4　(a) Concentration of IL-13 in serum. Samples were obtained from healthy volunteers 
(healthy), patients with AEP and CEP. Data are presented as the mean ± SD. healthy: n = 12, 
AEP: n = 4, CEP: n = 12. (b) Concentration of IL-13 in BALF. Samples were obtained from 
patients with AEP and CEP. Data are presented as the mean ± SD. AEP: n = 4, CEP: n = 12. 
*p < 0.05, compared with healthy and CEP.
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Table　2　Clinical features and concentrations of IL-33 in ARDS and AEP
Age M/F WBC  (×103/μl) P/F ratio 
CRP 
 (mg/dl)
Serum IL-33 
 (pg/ml)
BALF IL-33
 (pg/ml)
ARDS (n = 12) 69.7 ± 8.6* 8/4  7.5 ± 5.4  91.4 ± 23.8* 17.6 ± 7.1    1.0 ± 2.9   2.4 ± 6.2
AEP (n = 4) 22.0 ± 1.7 4/0 18.8 ± 6.8 215.6 ± 48.9 16.2 ± 7.2 1344.0 ± 1095.0* 616.1 ± 665.7*
*p < 0.05, compared between ARDS and AEP.
Table　3　Concentration of serum IL-33 in CEP with or without atopic disease
Age M/F WBC  (×103/μl)
Eosinophil 
(×103/μl) IgE (IU/ml)
Serum IL-33 
(pg/ml)
CEP with atopic disease 
(n = 7)
44.0 ± 22.5 3/4 11.6 ± 4.7 4.1 ± 2.8 1357.9 ± 1486.5* 255.3 ± 215.2
CEP without atopic disease 
(n = 5)
60.8 ± 26.0 3/2 11.9 ± 2.3 2.9 ± 1.0  206.5 ± 93.4 undetectable
*p < 0.05, compared between CEP with or without atopic disease.
indicated a wide range of titers of IL-33 (148.9 ± 203.9
pgml). In this study, fifty-eight percent of CEP pa-
tients (7 patients) had a history of atopic disease such
as bronchial asthma or allergic conjunctivitis or rhini-
tis; therefore, we focused our attention on atopic dis-
ease and divided CEP patients into two groups ac-
cording to those with or without atopic disease and
compared serum IL-33 levels (Table 3). CEP patients
with atopic disease had significantly elevated serum
levels of IgE and IL-33 (255.3 ± 215.2 pgml). In con-
trast, IgE was almost within the normal range and IL-
33 was undetectable in non-atopic CEP patients.
DISCUSSION
Several experiments employing rodents have demon-
strated that IL-33 played important roles in allergic
disease1,7,8; however, studies focusing on the clinical
significance of IL-33 in humans have been few.9-11 In
this study, we investigated the IL-33 level in EP pa-
tients and demonstrated that IL-33 was especially in-
creased in both serum and BALF in AEP. This is the
first report to evaluate the level and significance of IL-
33 in EP.
In the present study, the level of BALF IL-33 was
significantly increased in patients with AEP; it was
394.7 ± 318.8 pgml, which was estimated to be about
20% of that of serum levels (1344.0 ± 1095.0 pgml).
Allen et al. previously pointed out that a high concen-
tration of BALF IL-5 in patients with AEP suggested
the local production of IL-5 in lungs.19 BAL is gener-
ally performed by a large volume of saline, and BALF
normally contains approximately 1100 of the usual
plasma protein concentration.23 Therefore, the high
concentration of BALF IL-33 in AEP suggests that IL-
33 is also locally produced in the lungs and released
into the airway. Although histological analysis could
not be performed in this study, several reports have
demonstrated the increase of IL-33 expression in epi-
thelial cells of the lung.1,24 Considering the high val-
ues in BALF, airway epithelial cells are regarded as a
main candidate for the IL-33-producing cells in AEP.
In the in vitro experiment, it was elucidated that in-
tracellular IL-33 was cleaved by caspase-3 or -7 and
became biologically inactive in apoptotic cells25;
meanwhile, IL-33 was released as an active full-length
form from necrotic cells.25,26 Pathological findings of
AEP are traditionally characterized as diffuse alveolar
damage; therefore, we initially expected that local in-
crease of IL-33 in AEP was derived from cell necrosis
by severe lung injury. Then, to confirm whether the
release of IL-33 actually depended on the tissue dam-
age, we also analyzed IL-33 levels in patients with
ARDS, which was a representative disorder with
acute lung injury. To our surprise, we found no in-
crease of IL-33 in serum and BALF, despite severe
respiratory failure and pulmonary parenchymal dam-
age. From this result, we know that release of IL-33 is
not simply dependent on tissue injury; it is likely that
specific mechanisms to induce IL-33 are activated in
AEP. Cigarette smoking is regarded as a main trigger
of AEP, and several impressive studies have docu-
mented how cigarette smoking elicited oxidative
stress and induced the release of lactate dehydroge-
nase and cell necrosis in airway epithelial cells.27,28
The precise mechanism of the release of IL-33 could
not be explored here; however, specific acute stimuli
like cigarette smoking are considered to be associ-
ated with cell necrosis and production of IL-33 in epi-
thelial cells in AEP. By contrast, it was reported that
serum IL-33 was decreased in patients with emphy-
sema who had long smoking histories.11 Further in
vivo and in vitro basic study is required to explore the
secretion pathway of IL-33 by cigarette smoking. On
the other hand, several studies have demonstrated
that apoptosis of epithelial cells is implicated in the
pathogenesis of ARDS29,30; namely, DNA fragmenta-
tion and increase of caspase-3 have been observed in
alveolar cells in ARDS. Together with the evidence
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that IL-33 was cleaved by caspase and inactivated dur-
ing apoptosis,25 we speculate that inactivation of IL-33
in apoptotic epithelial cells would contribute to the
very low values of IL-33 in ARDS.
Th2 cytokines, such as IL-4, IL-5, and IL-13 were
also examined in this study. Although these cytoki-
nes of sera were significantly elevated in AEP, only
IL-5 was significantly higher in both serum and BALF
in AEP, and the level of IL-5 was positively correlated
with that of IL-33. It was established that IL-33 in-
duces a Th2-immuno response via IL-4, IL-5, and IL-
13,1,5,6 but Kurowska-Stolarska et al. demonstrated
that IL-33 polarized naïve CD4 (+) cells into IL-5-
producing T cells predominantly and exacerbated air-
way inflammation independent of IL-4.31 Allakhverdi
et al. also showed that IL-33 stimulated hematopoietic
progenitor cells to release IL-5 and IL-13, but not IL-
4.32 In addition, Cherry et al. found that IL-33 has a
synergistic effect with IL-5 in the activation of eosino-
phils.5 Our study was consistent with previous stud-
ies in the strong correlation between IL-33 and IL-5; it
is likely that these two cytokines have a synergistic
effect in inducing pulmonary eosinophilia.
It was recently demonstrated that circulating hema-
topoietic progenitor cells had IL-33 receptors, and
when directly stimulated by IL-33, matured to be
eosinophils in an IL-5-dependent manner.32,33 In addi-
tion, under allergic conditions, hematopoietic pro-
genitors are distributed in pulmonary tissue and dif-
ferentiate to eosinophils locally, as well as in bone
marrow.34 In this study, IL-33 and IL-5 were strongly
induced in AEP compared with CEP, and based on
the function of IL-33 for the differentiation of eosino-
phils, it is speculated that IL-33 and IL-5 might con-
tribute not only the chemotaxis of mature eosinophils
from bone marrow, but also the local differentiation
of eosinophils from progenitors in the pulmonary tis-
sue in AEP. In addition, various cytotoxic proteins
from accumulated eosinophils, such as major basic
protein and eosinophil cationic protein, are able to
damage airway epithelial cells and possibly contrib-
ute to further necrosis and production of IL-33. Thus,
eosinophilia could be accelerated by IL-33, like a
paracrine loop, in the injured tissue of AEP.
On the other hand, IL-33 was hardly detected in
BALF of all patients with CEP, and only the seven
CEP patients with atopic disease showed a mild in-
crease of serum IL-33 (255.3 ± 215.2 pgml pgml),
equivalent to the levels previously reported in pa-
tients with atopic disease.9,11 Based on this result, we
speculate that the serum IL-33 level in CEP is de-
pendent on underlying atopic disease. Furthermore,
because eosinophilia is mildly pre-existing under the
influence of atopic disease or proceeds slowly in CEP,
rapid chemotaxis and differentiation of eosinophils by
IL-33 seems not to be a pivotal process in CEP.
Because of the few opportunities to encounter pa-
tients with EP, obtaining sufficient numbers of sub-
jects for analyses was difficult in the present study. In
the future, more large-scale studies are needed to ex-
plore the clinical implication of IL-33. In addition, in
this study, we selected ELISA as a method to detect
IL-33 protein. We could quantify the level of IL-33 by
ELISA; however, this procedure could not visualize
the molecular weight of IL-33. It has been believed
that full-length IL-33 is the only biologically active
form,25,26,35 however, Lefrançais et al. recently dem-
onstrated that IL-33 cleaved by neutrophil elastase or
cathepsin G showed stronger biological activities
than full-length IL-33.36 This evidence suggests the
possibility that highly active IL-33 derived from in-
flammatory tissue contains not only full-length IL-33
but also IL-33 variously cleaved by several proteases
released from inflammatory cells. In future, we will
investigate the varieties of IL-33 in patients with EP
by western blotting.
Regardless of this limitation, and in spite of the
small scale of this study, we believe our findings pro-
vide a basis to develop future investigations of IL-33
and pulmonary eosinophilia.
In conclusion, IL-33 is considered to be a local key
molecule for triggering pulmonary eosinophilia in
AEP, together with IL-5. BALF IL-33 appears to be a
very useful marker for discriminating AEP from CEP
and ARDS.
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